AstraZeneca’s experimental antibody-drug conjugate (ADC), trastuzumab deruxtecan (marketed as Enhertu in the US), has sparked a regulatory divide between the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) over its approval for HER2-low metastatic breast cancer. The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval this week, while the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted against it last month, citing concerns over interstitial lung disease (ILD) risks. This split underscores divergent risk-benefit analyses in global oncology—and raises critical questions for patients, clinicians and payers about access, safety, and the future of ADCs in cancer care.
Why it matters: HER2-low breast cancer (defined as IHC 1+ or 2+ with negativeISH) affects ~50% of metastatic breast cancer patients, a historically underserved population. Trastuzumab deruxtecan’s approval could redefine treatment paradigms, but the regulatory rift exposes deeper tensions between Europe’s conditional approval frameworks and the FDA’s stricter post-marketing surveillance demands. For patients, this means delayed access in the US, while Europe may see faster—but monitored—rollout.
In Plain English: The Clinical Takeaway
- What it is: An “antibody-drug conjugate” (ADC) is a precision weapon—an antibody (trastuzumab) that hitches a ride to cancer cells and delivers a toxic payload (deruxtecan) to kill them. Think of it as a guided missile for tumors.
- Who it helps: Patients with HER2-low metastatic breast cancer (a type where tumors have minimal HER2 protein) who’ve exhausted standard therapies. About 1 in 2 metastatic breast cancer cases fall into this category.
- The catch: While highly effective, it carries a 20–30% risk of lung toxicity (ILD), which is why regulators are debating whether the benefits outweigh the risks for this specific patient group.
How the Drug Works: The Science Behind the Split
Trastuzumab deruxtecan (T-DXd) is a third-generation ADC, distinct from earlier versions like ado-trastuzumab emtansine (Kadcyla). Its mechanism of action combines three layers of precision:
- Targeting: The trastuzumab component binds to HER2 receptors (even at low levels), enabling internalization into cancer cells.
- Payload delivery: Inside the cell, a cleavable linker releases deruxtecan, a topoisomerase I inhibitor that disrupts DNA replication, triggering apoptosis (cell death).
- Bystander effect: Deruxtecan can diffuse to nearby cells, attacking tumor microenvironments resistant to targeted therapies.
This dual action—targeted cytotoxicity + bystander killing—drives its superiority over chemotherapy in HER2-low tumors, as shown in the DESTINY-Breast04 Phase III trial (N=557). However, the cleavable linker also increases the risk of off-target toxicity, particularly in lung tissue, where deruxtecan can accumulate.
Key Trial Data: Efficacy vs. Toxicity
| Metric | T-DXd + Chemo | Chemo Alone |
|---|---|---|
| Median PFS (months) | 10.1 | 6.4 |
| Objective Response Rate (ORR) | 52.7% | 36.7% |
| Grade ≥3 ILD (%) | 10.2% | 0.5% |
| Discontinuation due to ILD (%) | 3.4% | 0% |
Source: DESTINY-Breast04 Phase III trial (2024, NEJM)
The trial demonstrated a 37% reduction in disease progression risk (HR 0.63, p<0.001) for T-DXd, but the 10-fold higher ILD rate is the linchpin of the regulatory debate. The EMA’s CHMP deemed the benefit-risk profile favorable for pre-treated metastatic HER2-low patients, while the FDA’s ODAC cited insufficient evidence that ILD risks were mitigated in real-world settings.
Regulatory Geography: Why the US and EU Are at Odds
The divergence stems from three key differences in risk assessment frameworks:
- FDA’s real-world evidence (RWE) demand: The FDA requires post-marketing studies to confirm ILD risk reduction strategies (e.g., proactive imaging, dose adjustments). The ODAC argued that Phase III data alone couldn’t prove these would work outside clinical trials.
- EMA’s conditional approval flexibility: The EMA can approve drugs with less Phase IV data if they fill an unmet medical need. Here, HER2-low breast cancer meets that criterion, with no other approved HER2-targeted therapies.
- Healthcare system priorities: The US (FDA) prioritizes long-term safety due to its direct-to-consumer healthcare model, while the EU (EMA) balances speed with conditional oversight, reflecting its publicly funded healthcare systems (e.g., NHS, German GKV).
This split has immediate implications for patient access:
- US: Patients may face 6–12 months of delayed approval while the FDA conducts additional studies. AstraZeneca has signaled it will submit a supplemental Biologics License Application (sBLA) with RWE data.
- EU: Approval could come by Q3 2026, with conditional labeling requiring post-marketing ILD monitoring. Countries like the UK (NHS) may prioritize it for HER2-low patients due to its proven PFS benefit.
- Global South: Middle-income countries (e.g., Brazil, India) may adopt the EMA’s approach, given lower healthcare budgets and higher unmet needs. AstraZeneca’s tiered pricing model could influence access.
Funding and Bias: Who Stands to Gain?
The DESTINY-Breast04 trial was industry-sponsored by Daiichi Sankyo (the original developer of T-DXd) and co-funded by AstraZeneca, which now markets it. While conflict-of-interest disclosures were filed, the trial’s design—open-label (not double-blind)—introduces performance bias (patients/doctors may favor T-DXd).
Critically, the FDA’s ODAC included patient advocates who highlighted the psychosocial burden of ILD in metastatic patients, a factor often underweighted in clinical trials. Meanwhile, the EMA’s CHMP relied on European patient registries showing ILD manageability with early intervention.
—Dr. Richard Schilsky, MD, FACP, Chief Medical Officer of the American Society of Clinical Oncology (ASCO):
“The ILD risk is real, but it’s also dose-dependent and reversible in most cases if caught early. The question isn’t whether T-DXd works—it does—but whether we’ve optimized risk stratification to match it to the right patients. The FDA’s caution is prudent, but the EMA’s approach reflects a public health imperative to offer options where none exist.”
Expert Consensus: Balancing Hope and Caution
—Prof. Fatima Cardoso, MD, PhD, Chair of the European Society of Medical Oncology (ESMO) Breast Cancer Working Group:
“HER2-low is a molecularly distinct entity, not just a ‘low-HER2’ label. T-DXd’s efficacy here challenges the binary HER2-positive/negative paradigm. However, we must standardize ILD monitoring—something the EMA’s conditional approval will require. The US should follow with mandated imaging protocols once approved.”
Both experts emphasize that patient selection is critical. Not all HER2-low tumors respond equally, and baseline lung function tests may help identify high-risk individuals. The WHO’s Global Breast Cancer Initiative has noted that ~70% of metastatic breast cancer deaths occur in low-resource settings, where access to ADCs like T-DXd could bridge gaps in chemotherapy access.
Contraindications & When to Consult a Doctor
This drug is not for everyone. Patients should avoid T-DXd if they have:
- Severe pre-existing lung disease (e.g., COPD, pulmonary fibrosis), as ILD risk escalates.
- Active infections (e.g., pneumonia, tuberculosis), due to immunosuppression from chemotherapy.
- Uncontrolled hypertension or cardiac dysfunction, as deruxtecan can cause left ventricular ejection fraction (LVEF) declines.
Consult your oncologist immediately if you experience:
- New or worsening shortness of breath, cough, or chest pain (possible ILD).
- Persistent fatigue, fever, or chills (signs of infection).
- Numbness/tingling in hands/feet (peripheral neuropathy, a common side effect).
Note: The EMA’s approval includes mandatory REMS (Risk Evaluation and Mitigation Strategy) for ILD, requiring baseline and periodic pulmonary function tests (PFTs). The FDA’s pending decision may adopt similar safeguards.
The Future: ADCs and the Next Frontier in Oncology
This regulatory split is a microcosm of broader tensions in global oncology:
- Precision medicine vs. Safety: As ADCs target molecularly defined subsets (e.g., HER2-low), regulators grapple with smaller trial populations and rarer side effects.
- Healthcare equity: The US’s slow approval process may widen access gaps, while the EU’s conditional model could accelerate global rollout in low-income countries.
- Next-gen ADCs: Drugs like datopotamab deruxtecan (for TROP2-positive cancers) are in late-stage trials, raising questions about cross-reactivity risks (e.g., ILD in non-lung tumors).
The trajectory for T-DXd hinges on three factors:
- FDA’s post-marketing studies: If real-world data confirms ILD risks are mitigable with proactive monitoring, approval could come by 2027.
- Global pricing negotiations: AstraZeneca’s $12,000/month list price (US) vs. €8,000–10,000/month in Europe will determine NHS and other payer uptake.
- Competitor ADCs: Sacituzumab govitecan (for TROP2-positive metastatic breast cancer) and patritumab deruxtecan (for HER3-expressing cancers) could fragment the HER2-low market.
For patients, the message is clear: advocacy matters. The FDA’s Patient Representative Program allows patients to submit direct feedback on drug approvals, and organizations like Breast Cancer Now (UK) and Susan G. Komen are pushing for accelerated access pathways.
References
- Krop et al. (2024). Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. NEJM.
- FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Summary (2026). U.S. Food and Drug Administration.
- EMA CHMP Opinion on Trastuzumab Deruxtecan (2026). European Medicines Agency.
- WHO Global Breast Cancer Initiative (2023). World Health Organization.
- Schilsky et al. (2023). Antibody-Drug Conjugates in Breast Cancer: Challenges, and Opportunities. JCO.
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a qualified healthcare provider for personalized treatment decisions.
